Despite the in-vivo validation of the anti-cancer effects of juglone, its lack of specificity to Pin1 and the nature and diversity of its numerous off-target interactors limit the use of juglone as a potential cancer therapeutic. This evidence concerns the gene PIN1 and cancer.